Skip to main content

Our purpose is

to make every

pregnancy around

the world safer.

Learn More

Our mission is to develop and make globally available the first therapy targeting a root cause of preeclampsia.

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.

Learn About Our WorkMeet Our Team

The
Problem

Learn More

A
Breakthrough

Learn More

Our
Science

Learn More

Patient and Survivor Resources

Read our latest news

January 17, 2024

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Read More

August 28, 2023

Comanche Biopharma Named by Fierce Biotech as a “Fierce 15” Biotech Company of 2023

Read More

Contact Us

50 Beharrell St, Unit B
Concord, MA 01742

Contact Us

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.

Sign up to receive email updates

Translate 🌎 💬